文献速递急性肾损伤遗传性与小管间质肾病

全球aHUS登记研究:从依库珠单抗转换至雷夫利珠单抗的患者分析

Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab.
PubMed 文献 · Kidney Int Rep · 2024-06-20

基于全球aHUS登记研究,纳入60例从依库珠单抗转换至雷夫利珠单抗的成人和儿童患者,其中49例纳入有效性和遗传分析。转换后血液学和肾脏参数保持稳定,未报告新发透析、肾移植或血栓性微血管病事件,无脑膜炎球菌感染或死亡,仅3例治疗相关不良事件。

要点

  • 从依库珠单抗转换至雷夫利珠单抗后,肾脏和血液学参数保持稳定
  • 未报告新发透析、肾移植或血栓性微血管病事件
  • 无脑膜炎球菌感染或死亡,仅3例治疗相关不良事件

核心结论

  • 这是首个关于从依库珠单抗转换至雷夫利珠单抗的aHUS患者真实世界队列分析,强化了雷夫利珠单抗在该人群中的真实世界安全性和有效性数据。

研究设计与样本

  • 全球aHUS登记研究为多中心研究(NCT01522183),收集成人或儿童aHUS患者数据,无论治疗情况。
  • 共60例患者转换至雷夫利珠单抗(成人43例,儿童17例),其中11例因雷夫利珠单抗治疗不足3个月和/或依库珠单抗停药至雷夫利珠单抗启动间隔超过1个月而被排除于有效性和遗传分析,最终49例纳入分析(成人40例,儿童9例)。

主要发现

  • 49例患者中11例(22%)检出致病性补体变异,最常见为补体因子H变异(5/49,10%)。
  • 雷夫利珠单抗治疗期间,13例患者发生20例不良事件,无意外不良事件,仅3例为治疗相关不良事件(输注反应、头痛和疲劳)。
  • 未报告脑膜炎球菌感染或死亡,未报告新发透析、肾移植或血栓性微血管病事件。
  • 转换至雷夫利珠单抗后,肾脏和血液学参数保持稳定。

临床怎么用

  • 对于已接受依库珠单抗治疗的aHUS患者,转换至雷夫利珠单抗后肾脏和血液学参数保持稳定,未报告新发透析、肾移植或血栓性微血管病事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death. Ravulizumab, a next-generation terminal complement inhibitor, provides immediate, complete, and sustained complement C5 inhibition. Real-world data in patients with aHUS who switched to ravulizumab from eculizumab are lacking. METHODS: The Global aHUS Registry is a multicenter study (NCT01522183) collecting data on adult or pediatric patients with an aHUS diagnosis, regardless of treatment. Patient characteristics, genetic data, hematological and renal parameters, clinical events (e.g., dialysis and kidney transplantation), and adverse events (AEs) were extracted from patients who switched to ravulizumab from eculizumab up to July 3, 2023. RESULTS: Overall, 60 patients switched to ravulizumab (adult: n = 43; pediatric: n = 17); 11 patients were excluded from effectiveness and genetic analyses (N = 49; adult: n = 40; pediatric: n = 9) because they received <3 months ravulizumab treatment and/or had >1 month between eculizumab discontinuation and ravulizumab initiation. Pathogenic complement variants were identified in 11 of 49 patients (22%); the most common was a complement factor H variant (n = 5/49 [10%]). During ravulizumab treatment, 20 AEs occurred in 13 patients, with no unexpected AEs and only 3 treatment-related AEs (infusion reaction, headaches, and fatigue). No meningococcal infections or deaths were reported. No new events of dialysis, kidney transplantation, or thrombotic microangiopathy were reported. Renal and hematological parameters remained stable after switching to ravulizumab. CONCLUSION: This is the first real-world cohort analysis of data from patients treated with ravulizumab and reinforces the real-world safety and effectiveness data of ravulizumab in patients with aHUS who switched from eculizumab.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Schaefer F, Al-Dakkak I, Anokhina K, et al. Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab. Kidney Int Rep. 2024. PMID: 39291212. doi:10.1016/j.ekir.2024.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。